Navigation Links
BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference

ary 4, 2007 awarded BioCryst a $102.6 million, four-year contract to develop peramivir for the treatment of seasonal and life-threatening influenza. Funding from the contract will support Phase II and Phase III product development activities including manufacturing of clinical lots, process validation, clinical studies and other product approval requirements needed for U.S. licensure. BioCryst retains 100% development and commercialization rights to peramivir worldwide other than in Japan and Korea where BioCryst recently established strategic partnerships with Shionogi & Co. in Japan, and Green Cross in Korea.

About Peramivir

Peramivir is a member of the class of antiviral agents that inhibit influenza viral neuraminidase, an enzyme that is essential for the spread of influenza virus within the host. Peramivir is an inhibitor of influenza A and B neuraminidases and certain strains of influenza viruses that may be resistant to available neuraminidase inhibitors but are susceptible to peramivir in laboratory tests. At the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in September, 2006, data were presented showing that injectable formulations of peramivir were safely administered to healthy subjects at daily doses up to approximately 600 mg. At the same meeting, animal data were presented showing peramivir promoted survival in animals infected with highly pathogenic strains of the H5N1 virus. Peramivir injection has received Fast Track designation from US FDA and the availability of an intravenous neuraminidase inhibitor may be important in treating patients hospitalized with severe and potentially life-threatening influenza. The availability of an intramuscular formulation of peramivir could ensure appropriate dosing which may be a concern with currently available oral or inhaled anti-influenza agents.

About Influenza

The influenza virus causes an acute viral disease of the respiratory tract. Unlike the
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
(Date:7/2/2015)... Research and ... of the "2015 New Frontiers in ... Technologies, Competitive Landscape" report to their ... Clinical Chemistry and Immunodiagnostics: Global Challenges, Emerging ... strategic analysis of major business opportunities emerging ...
(Date:7/2/2015)...  AbbVie (NYSE: ABBV ) will announce its ... before the market opens. AbbVie will host ... 8 a.m. Central time (9 a.m. Eastern). It will ... www.abbvieinvestor.com . An archived edition of the call will ... About AbbVie AbbVie is a global, research-based ...
(Date:7/2/2015)... -- Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced ... in the Southern District of West Virginia ... Ethicon for a single trial to take place on ... women include claims from the women plaintiffs that they ... Johnson,s Ethicon subsidiary. The cases against Ethicon are among ...
Breaking Medicine Technology:New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3
... GAITHERSBURG, Md.--(BUSINESS WIRE)--Apr 17, 2007 - GenVec, ... presented at,the 97th annual meeting of the ... support the use of adenovector systems,to deliver ... lead product candidate, TNFerade(TM) biologic (TNFerade),is an ...
... Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Curis, Inc.,(NASDAQ:CRIS), ... targeted,medicines primarily for cancer treatment, today announced ... at the 98th Annual Meeting,of the American ... Curis also disclosed that its April 2005 ...
Cached Medicine Technology:GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy 2GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy 3Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 2Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 3Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 4
(Date:7/2/2015)... ... July 02, 2015 , ... B. E. Smith, ... retained to lead a national chief executive officer recruitment for Indiana ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
(Date:7/2/2015)... ... July 02, 2015 , ... After conducting a nationwide ... Regional Medical Center in Yuma, Ariz., has hired Robert Trenschel, DO, as chief ... medical management, Dr. Trenschel will assume his new duties at Yuma Regional Medical Center ...
(Date:7/2/2015)... ... July 02, 2015 , ... The report summarizes ... manufacturers. The report is a valuable source of guidance and direction for companies ... Chinese market for the Gelatin Capsule industry including capacity, production, production value, cost ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... is announcing with their launch an intention to partner with companies that share ... on the planet. Their innovative water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic ...
(Date:7/2/2015)... ... ... DUI arrests and fatalities spike on the 4th of July. In fact, because of drunk ... comes to being on the road. According to attorney David J. Maloney , the ... highway deaths between 2007 and 2011 were caused by drunk driving over the 4th of ...
Breaking Medicine News(10 mins):Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 3Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:Attorney David Maloney Stresses Safety through Sobriety 2
... 2 in the morning helped adults lose 65% more weight, ... eggs may help overweight adults lose weight and feel more ... of overweight or obese adults, ages 25 to 60, found ... of a calorie-reduced diet lost 65 percent more weight, had ...
... cancer patients and their physicians may make more informed, ... determine probability of recurrence, a research team led by ... Cancer Center reported in the Aug. 12 online issue ... . , The 2,838 women studied were diagnosed with ...
... As more people send text messages, repetitive strain injury cases are on ... ... 12 SpinVox, the leader in voice-to-content,messaging, today issued new guidelines to ... of all ages texting furiously at all hours of the day, we,are ...
... person with a disability, MINNEAPOLIS, Aug. 12 ... for people with disabilities, is seeking,applications for its ... 1992, the Jacobson Award recognizes the pursuit or,achievement ... with a,physical disability or sensory impairment. The award ...
... New study fails to settle question about best treatment ... -- The latest update from a European study that ... a decade leaves the debate about the advantages of ... in survival seen for men who underwent surgery to ...
... The Quantum Group,Inc. (Amex: QGP ) ... today that Noel J. Guillama, President &,CEO, will ... Conference at,5:00 p.m. (Pacific) on Monday, August 18, ... Mr. Guillama will give a 23-minute presentation ...
Cached Medicine News:Health News:Risk assessment plays key role in long-term treatment of breast cancer 2Health News:SpinVox Offers New Guidelines to Prevent Repetitive Strain Injuries 2Health News:SpinVox Offers New Guidelines to Prevent Repetitive Strain Injuries 3Health News:Courage Center Seeks Applications for Judd Jacobson Memorial Award 2Health News:Surgery Helps With Prostate Cancer, Sometimes 2Health News:Surgery Helps With Prostate Cancer, Sometimes 3Health News:The Quantum Group to Present at the Noble Financial Equity Conference 2Health News:The Quantum Group to Present at the Noble Financial Equity Conference 3
For rotating nucleus during phacoemulsification, Also useful for dislocating the nucleus into the anterior chamber during extracapsular cataract extraction, 45, Blunt, Forked, 9.0mm from end...
... has two perforations which enable ... various single or bilateral configurations ... drape has two perforations which ... to various single or bilateral ...
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Designed for use in traditional external approach DCRs in pediatric patients & for endoscopic DCRs in adults or children. Lumen 6.0mm long, ID-1.4mm (.12 in); OD-5.0mm (.20 in), Outer flanges 8.0mm ...
Medicine Products: